LGND:NASDAQ
Ligand Pharmaceuticals Inc
$283.49
arrow_downward
-0.43%(-1.21) 1D
$283.49
arrow_upward
+0.00% (+0.0025)bedtimeAfter hours
Closed: Sep 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LGND...
Open
$285.63
High
$285.64
Low
$280.49
Mkt. cap
5.65B
Avg. vol.
219.20K
Volume
372.80K
P/E ratio
30.15
52-wk high
$326.63
52-wk low
$163.45
EPS
$9.40
Beta
1.03
Shares outstanding
19.94M
No. of employees
47
Open
$285.63
High
$285.64
Low
$280.49
Mkt. cap
5.65B
Avg. vol.
219.20K
Volume
372.80K
P/E ratio
30.15
52-wk high
$326.63
52-wk low
$163.45
EPS
$9.40
Beta
1.03
Shares outstanding
19.94M
No. of employees
47
News stories
From web sources and news partners
CarePlus VietNam
·
1 month ago
Ligand (LGND) Latest Results Brief: EPS Exceeds Its Estimate on the Day; Price Action: The Stock Ends Down 1.27% in Latest Trading - Final Results
CarePlus VietNam
·
1 month ago
LGND Q1 2026 Earnings: EPS Misses Estimates, Stock Slightly Down - Guidance Accuracy Score
CarePlus VietNam
·
2 months ago
Ligand Pharmaceuticals (LGND) Slides 2.57% as Shares Test Key Support Levels - Monthly Profile
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
FoundedSep 1987
HeadquartersJupiter, Florida, United States
SectorPharmaceutical industry
Websiteligand.com